Show simple item record

dc.contributor.authorGershkovich, Pavel
dc.contributor.authorBenito, Paloma
dc.date.accessioned2016-09-20T10:41:33Z
dc.date.available2016-09-20T10:41:33Z
dc.date.issued2016-08-24
dc.identifier.urihttps://rdmc.nottingham.ac.uk/handle/internal/59
dc.description.abstractLipidic formulations (LFs) are increasingly utilized for the delivery of drugs that belong to class II of the Biopharmaceutics Classification System (BCS). The current work proposes, for the first time, the combination of in vitro lipolysis and microsomal metabolism studies for the quantitative prediction of human oral bioavailability of BCS II drugs administered in LFs. Marinol® and Neoral® were selected as model LFs and their observed oral bioavailabilities (Fobserved) obtained from published clinical studies in humans. Two separate lipolysis buffers, differing in the level of surfactant concentrations, were used for digestion of the LFs. The predicted fraction absorbed (Fabs) was calculated by measuring the drug concentration in the micellar phase after completion of the lipolysis process. To determine first-pass metabolism (Fg∙Fh), drug depletion studies with human microsomes were performed. Clearance values were determined by applying the “in vitro half-life approach”. The estimated Fabs and Fg∙Fh values were combined for the calculation of the predicted oral bioavailability (Fpredicted). Results showed that there was a strong correlation between Fobserved and Fpredicted values only when Fabs was calculated using a buffer with surfactant concentrations closer to physiological conditions. The general accuracy of the predicted values suggests that the novel in vitro lipolysis/metabolism approach could quantitatively predict the oral bioavailability of lipophilic drugs administered in LFs.en_UK
dc.language.isoenen_UK
dc.publisherThe University of Nottinghamen_UK
dc.relation.urihttp://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.6b00597en_UK
dc.subject.lcshDrug carriers (Pharmacy)en_UK
dc.subject.lcshLipolysisen_UK
dc.subject.lcshDrugs -- Absorption and adsorption -- Researchen_UK
dc.subject.lcshDrugs -- Absorption and adsorption -- Mathematical modelsen_UK
dc.subject.lcshDrugs -- Designen_UK
dc.subject.lcshDrugs -- Bioavailabilityen_UK
dc.subject.lcshPharmacokineticsen_UK
dc.titleIn vitro lipolysis/microsomal metabolism approach for the prediction of oral bioavailability of BCS II drugs in lipidic formulationsen_UK
dc.identifier.doihttp://doi.org/10.17639/nott.56
dc.subject.freein vitro lipolysis, microsomal metabolism, IVIVC, oral bioavailability, Δ9-tetrahydrocannabinol, cyclosporine Aen_UK
dc.subject.jacsSubjects Allied to Medicine::Pharmacology, toxicology & pharmacy::Pharmacology, toxicology & pharmacy not elsewhere classifieden_UK
dc.subject.lcR Medicine::RS Pharmacy and materia medicaen_UK
dc.date.collection2015-2016en_UK
uon.divisionUniversity of Nottingham, UK Campus::Faculty of Science::School of Pharmacyen_UK
uon.funder.controlledEngineering & Physical Sciences Research Councilen_UK
uon.datatypeExcel files with raw and processed data corresponding to the publication Benito-Gallo P., et al. Mol Pharm. (2016)en_UK
uon.grantEP/I01375X/1en_UK
uon.collectionmethodIn vitro lipolysis, microsomal incubations, HPLC-UV, HPLC-MS/MS, Graphpaden_UK
uon.rightscontactThe University of Nottinghamen_UK
uon.preservation.rarelyaccessedtrue
dc.relation.doi10.1021/acs.molpharmaceut.6b00597en_UK


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record